Immunotherapy Linked to Hyperprogression of NSCLC and Other Cancers – Targeted Oncology
|
Immunotherapy Linked to Hyperprogression of NSCLC and Other Cancers
Targeted Oncology Awareness of hyperprogression—a rapid increase in tumor growth after initiation of immunotherapy—has been increasing since a 2016 French study first defined hyperprogression in a population of patients receiving anti–PD-1/PD-L1 therapy for melanoma … |
